2Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV- infected adults and adolescents recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep, 2009,58 (RR-4) : 1-207 ; quizCE1-4.
4Selabe SG, Lukhwareni A, Song E, et al. Mutations associated with lamivudine-resistance in therapy-naive hepatitis B virus (HBV) infected patients with and without HIV co-infection: Implications for antiretroviral therapy in HBV and HIV co-infected South African patients. J Med Virol, 2007,79 : 1650-1654.
5Vincenti D, Solmone M, Garbuglia AR, et al. A sensitive direct sequencing assay based on nested PCR for the detection of HBV polymerase and surface glycoprotein mutations. J Virol Methods, 2009,159:53-57.
7Wolters LM, Niesters HG, Hansen BE, et al. Development of hepatitis B virus resistance for lamivudine in chronic hepatitis B patients co-infected with the human immunodefieiency virus in a Dutch eohort. J Clin Virol, 2002,24 : 173-181.
8Iacomi F, Vincenti D, Vairo F, et al. Effect of HIV coinfection on mutation patterns of HBV in patients with lamivudine-resistant chronic hepatitis B. J Med Virol, 2009,81:1151-1156.
9Matthews GV, Bartholomeusz A, Locarnini S, et al. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS, 2006,20 : 863-870.
10Jardi R, Rodriguez-Frias F, Schaper M, et al. Analysis of hepatitis B genotype changes in chronic hepatitis B infection: Influence of antiviral therapy. J Hepatol,2008,49 : 695-701.
